Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT02471183
Previous Study | Return to List | Next Study

Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Patients With Pulmonary Arterial Hypertension (TRANSIT-1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02471183
Recruitment Status : Completed
First Posted : June 15, 2015
Results First Posted : December 28, 2017
Last Update Posted : January 23, 2018
Sponsor:
Information provided by (Responsible Party):
Actelion

Brief Summary:
This study enrolls patients with pulmonary arterial hypertension (PAH) treated with inhaled treprostinil. During the study, the treatment with inhaled treprostinil will be tapered off and simultaneously replaced with an oral treatment (selexipag) targeting the disease in a similar way. The purpose of the study is i) to investigate the safety and tolerability of oral selexipag in patients who transition from inhaled treprostinil, ii) to investigate the effects of oral selexipag on PAH severity and exercise ability before and after transition, and iii) to gain new information about the patients experience taking oral selexipag compared to inhaled treprostinil. Study participants may stay in the study until the FDA has granted marketing authorization.

Condition or disease Intervention/treatment Phase
Pulmonary Arterial Hypertension Drug: Selexipag Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 34 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Multicenter, Open-label, Single-group Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Adult Patients With Pulmonary Arterial Hypertension
Actual Study Start Date : October 12, 2015
Actual Primary Completion Date : December 5, 2016
Actual Study Completion Date : December 5, 2016


Arm Intervention/treatment
Experimental: Selexipag, Open Label

Subjects on inhaled treprostinil treatment participate in a 16-week main treatment period including down-titration of treprostinil to end of Week 8 and parallel up-titration of selexipag to the maximum tolerated dose (MTD) up to Week 12, for each individual patient but not above 1600 mcg twice daily.

From Week 12 up to Week 16, patients continue selexipag at their individual MTD. Patients could continue the study drug selexipag during the extended treatment period from Week 16 until commercial availability of selexipag.

Drug: Selexipag
Tablets for oral administration containing 200 micrograms (mcg) of selexipag to be administered twice a day. The individual dose is to be established during the first 12 weeks of the study. Doses are in the range from 200 micrograms (1 tablet) to 1,600 micrograms (8 tablets).
Other Names:
  • Uptravi
  • ACT-293987




Primary Outcome Measures :
  1. Percentage of Subjects With Sustained Treatment Transition [ Time Frame: At Week 16 ]

    A sustained treatment transition is considered if the 3 following criteria are met a) being on study treatment (selexipag) at Week 16, and b) not having a study treatment interruption(s) of a total of 8 days or more prior to Week 16, and c) absence of inhaled treprostinil or any prostanoid treatment after Week 8 up to Week 16.

    The percentage of subjects with a sustained treatment transition is calculated with 95% confidence interval (CI) using the Clopper-Pearson method.


  2. Percentage of Subjects With Treatment-emergent Adverse Events (AEs), [ Time Frame: 26 weeks on average (from the first dose of selexipag up to 30 days after the last dose of selexipag) ]
    Percentage of subjects with treatment-emergent AEs (serious and non serious), regardless of relationship to selexipag

  3. Number of Subjects With Adverse Events Leading to Premature Discontinuation of Selexipag [ Time Frame: Up to 22 weeks on average ]
    Number of subjects with adverse events leading to premature discontinuation of selexipag is determined from the first dose of selexipag up to the last dose of selexipag

  4. Absolute Change From Baseline Over Time in Blood Pressure [ Time Frame: Baseline, Week 4, Week 12, Week 16 ]
    Both systolic(SBP) and diastolic (DBP) arterial blood pressure were measured in a sitting position after at least 5 minutes of rest at scheduled time points. Median change from baseline to pre-specified post-baseline visits are calculated

  5. Absolute Change From Baseline Over Time in Heart Rate (HR) [ Time Frame: Baseline, Week 4, Week 12, Week 16 ]
    Pulse rate is measured after at least 5 minutes of rest in a sitting position. Median change from baseline to pre-specified post-baseline visits are calculated.

  6. Maximal Tolerated Dose [ Time Frame: At Week 12, in subjects still on selexipag at Week 16 ]

    This is the individual maximal tolerated dose (MTD) observed at Week 12 in the subjects still on selexipag at Week 16.

    MTD is defined as the dose of selexipag reached with the last dose change up to Week 12


  7. Time to Discontinuation of Inhaled Treprostinil. [ Time Frame: Baseline to Week 16 ]
    Median time from baseline (Day1) to the end of down-titration of inhaled treprostinil is calculated


Secondary Outcome Measures :
  1. Percentage of Subjects With WHO Functional Class (FC) Change From Baseline [ Time Frame: Baseline and Week 16 ]

    The World Health Organization (WHO) defines 4 classes to classify the functional status of patients with pulmonary hypertension:

    Class I (FC I): No limitation of physical activity. Class II (FC II): Slight limitation of physical activity. Class III (FC III): Marked limitation of physical activity. Class IV (FC IV): Inability to carry out any physical activity without symptoms.

    Number of patients with improvement (shift from a higher to a lower class), worsening (shift from a lower to a higher class) or no change in WHO functional class at end of study compared to baseline are determined.


  2. Absolute Change in 6-minute Walk Distance (6MWD) at Trough [ Time Frame: Baseline and Week 16 ]

    The 6MWT is a non-encouraged test, which measures the distance (in meters) covered by the subject during a 6-minute walk. It is performed in a 30-meters long flat corridor, where the patient is instructed to walk as far as possible, back and forth around two cones, with the permission to slow down, rest, or stop if needed.

    Absolute change from baseline to Week 16 in 6MWD is measured at trough levels of inhaled treprostinil and/or selexipag. The trough level of inhaled treprostinil is defined as the last dose having been taken not less than 4 hours and not more than 48 hours prior to the 6MWT at Visit 1 (screening). The trough level of selexipag was defined as the last dose having been taken not less than 8 hours and not more than 7 days prior to the 6MWT at Visit 5 (Week 16).


  3. Percentage of Patients With Change in 6-minute Walk Distance (6MWD) [ Time Frame: Baseline and Week 16 ]

    Percentage of patients with an increase (> 8% of baseline), maintenance (+/- 8% of baseline), or decrease (< -8% of baseline) in their 6MWD (at trough) from baseline to Week 16. The ± 8% boundaries for change in 6MWD reflect the approximately 8% coefficient of variation in the reproducibility of the 6MWD.

    The trough level of inhaled treprostinil is defined as the last dose having been taken not less than 4 hours and not more than 48 hours prior to the 6MWD test at Visit 1 (screening). The trough level of selexipag was defined as the last dose having been taken not less than 8 hours and not more than 7 days prior to the 6MWD test at Visit 5 (Week 16).


  4. Geometric Mean of the Ratio in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) of Week 16 to Baseline [ Time Frame: Baseline and Week 16 ]
    Changes in NT-proBNP levels in plasma are expressed by the geometric mean of the ratio of Week 16 to baseline


Other Outcome Measures:
  1. Change From Baseline to Week 16 in the Treatment Satisfaction Questionnaire for Medication Questionnaire (TSQM II) [ Time Frame: Baseline and Week 16 ]

    The Treatment Satisfaction Questionnaire for Medication, Version II (TSQM II) is a validated tool that evaluate the subject's satisfaction with the study treatment. It includes a total of 11 questions related to satisfaction with treatment effectiveness, side effects,convenience, and global satisfaction.

    TSQM scores range from 0 to 100 for each domain; a higher score indicates higher satisfaction with treatment.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male and female patients aged from 18 to 75 years (inclusive) with pulmonary arterial hypertension (PAH).
  • Etiology of PAH belonging to one of the following subgroups: idiopathic PAH, Heritable PAH, drug or toxin induced, associated with connective tissue disease, associated with HIV infection, associated with congenital heart disease with simple systemic-to-pulmonary shunt at least 1 year after surgical repair.
  • Women of childbearing potential are eligible only if the following apply: Negative serum pregnancy test at Visit 1 and a negative urine pregnancy test at Visit on Day 1, agreement to undertake monthly urine pregnancy tests during the study and up to 30 days after study drug discontinuation, agreement to use efficient methods of birth control from Visit 1 up to at least 30 days after study treatment discontinuation.
  • Documented hemodynamic diagnosis of PAH by right heart catheterization (RHC).
  • Inhaled treprostinil treatment ongoing for at least 90 days and at stable dose for at least 30 days prior to Day 1.
  • WHO functional class (FC) II or III at Visit 1 and Visit 2.
  • 6-minute walk distance (6MWD) ≥ 300 m at Visit 1.
  • On background oral PAH therapy for at least 90 days and on a stable dose for 30 days prior to Visit 2. Acceptable concomitant PAH therapies are one or two of the following: a) Endothelin receptor antagonist (ERA), b) Phosphodiesterase type 5 (PDE-5) inhibitor or soluble guanylate cyclase (sGC) stimulator.

Exclusion Criteria:

  • Treatment with any prostacyclin or prostacyclin analogs other than inhaled treprostinil within 90 days before Day 1, or patients scheduled to receive any of these treatments within the duration of the study.
  • Any hospitalization within 90 days before Day 1.
  • Worsening in WHO FC within 30 days prior to Day 1.
  • At any time prior to Day 1, documented moderate or severe obstructive or restrictive lung disease.
  • Known or suspicion of pulmonary veno-occlusive disease (PVOD).
  • Anemia: < 80 g/L (5.0 mmol/L) hemoglobin.
  • Clinically relevant thyroid disease (hypo- or hyperthyroidism).
  • Known and documented severe hepatic impairment.
  • Uncontrolled hypertension.
  • Sitting systolic blood pressure < 85 mmHg.
  • Acute myocardial infarction within the last 90 days prior to Visit 1.
  • History of left-sided heart disease.
  • Left ventricular disease/dysfunction risk factors.
  • Documented pericardial effusion within 90 days prior to Visit 1.
  • Documented severe renal insufficiency.
  • Receiving or having received any investigational drugs within 90 days before Day 1.
  • Having received selexipag at any time before Day 1.
  • Acute or chronic impairment (other than dyspnea), limiting the ability to comply with study requirements.
  • Recently conducted or planned cardio-pulmonary rehabilitation program based on exercise training during the study.
  • Psychotic, addictive or other disorder limiting the ability to provide informed consent or to comply with study requirements.
  • Known concomitant life-threatening disease with a life expectancy < 12 months.
  • Females who are lactating or pregnant or plan to become pregnant during the study.
  • Known hypersensitivity to any of the excipients of the drug formulation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02471183


Locations
Layout table for location information
United States, California
UCSD Medical Center -La Jolla
La Jolla, California, United States
UCSF Medical Center
San Francisco, California, United States
Harbor UCLA Medical Center
Torrance, California, United States
United States, Georgia
Emory University
Atlanta, Georgia, United States
Piedmont Healthcare Research Institute
Austell, Georgia, United States
United States, Kentucky
Kentuckiana Pulmonary Associates
Louisville, Kentucky, United States
United States, Michigan
University of Michigan Health System
Ann Arbor, Michigan, United States
United States, Missouri
Washington University School of Medicine
Saint Louis, Missouri, United States
United States, North Carolina
Duke Unversity
Durham, North Carolina, United States
United States, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Allegheny General Hospital
Pittsburgh, Pennsylvania, United States
University of Pittsburgh Medical Center Health System
Pittsburgh, Pennsylvania, United States
United States, Texas
UT Southwestern
Dallas, Texas, United States
Houston Methodist Hospital
Houston, Texas, United States
United States, Virginia
Sentara Cardiovascular Research Instistute
Norfolk, Virginia, United States
Sponsors and Collaborators
Actelion

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Actelion
ClinicalTrials.gov Identifier: NCT02471183    
Other Study ID Numbers: AC-065A304
First Posted: June 15, 2015    Key Record Dates
Results First Posted: December 28, 2017
Last Update Posted: January 23, 2018
Last Verified: December 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Familial Primary Pulmonary Hypertension
Hypertension
Vascular Diseases
Cardiovascular Diseases
Hypertension, Pulmonary
Lung Diseases
Respiratory Tract Diseases
Treprostinil
Selexipag
Antihypertensive Agents